OTCMKTS:MEDGF Medacta Group (MEDGF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MEDGF Stock Alerts $83.91 0.00 (0.00%) (As of 04/15/2024) Add Compare Share Share Today's Range$83.91▼$83.9150-Day Range$83.91▼$83.9152-Week Range$83.91▼$86.33Volume1 shsAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Medacta Group alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Medacta Group Stock (OTCMKTS:MEDGF)Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine procedures. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.Read More MEDGF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDGF Stock News HeadlinesApril 16, 2024 | finance.yahoo.comOwning 70% in Medacta Group SA (VTX:MOVE) means that insiders are heavily invested in the company's futureApril 11, 2024 | markets.businessinsider.comMedacta announces the 10th M.O.R.E. International Symposium in Lugano, Switzerland, celebrating its 25th anniversary worldwideApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 9, 2024 | markets.businessinsider.comMedacta publishes 2024 Annual General Meeting invitationApril 2, 2024 | finance.yahoo.comInvesting in Medacta Group (VTX:MOVE) a year ago would have delivered you a 24% gainMarch 19, 2024 | finance.yahoo.comMedacta Group Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comEarnings Miss: Medacta Group SA Missed EPS By 24% And Analysts Are Revising Their ForecastsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Medacta Group’s Strong Growth and Market Position Outweigh Temporary Financial SetbacksApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 19, 2024 | ca.finance.yahoo.comMedacta Group SA (MOVE.SW)February 2, 2024 | markets.businessinsider.comMedacta Group SA: Medacta Group SA revenues up +19.5% at constant currency1 exceeding the milestone of 500Mln € in FY 2023January 30, 2024 | morningstar.comMedacta Group SA Ordinary Shares MOVEJanuary 18, 2024 | finance.yahoo.comA Look At The Intrinsic Value Of Medacta Group SA (VTX:MOVE)November 29, 2023 | markets.businessinsider.comMedacta further expands in Rancate, Switzerland, doubling its production capability to support the future growthNovember 23, 2023 | finance.yahoo.comMedacta Group (VTX:MOVE) Will Want To Turn Around Its Return TrendsOctober 25, 2023 | finance.yahoo.comAfter the recent decline, Medacta Group SA (VTX:MOVE) CEO Francesco Siccardi's holdings have lost 6.0% of their valueOctober 12, 2023 | markets.businessinsider.comA new study confirms the accuracy of NextAR Shoulder, Medacta’s augmented reality surgical applicationOctober 11, 2023 | finance.yahoo.comIf EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An OpportunitySeptember 22, 2023 | markets.businessinsider.comMedacta Group SA reports strong revenue growth at 21.4% at constant currency and adjusted EBITDA margin at 28.2% in the first semester 2023August 10, 2023 | finance.yahoo.comCalculating The Fair Value Of Medacta Group SA (VTX:MOVE)July 28, 2023 | markets.businessinsider.comMedacta Group SA: 2023 Half-Year Unaudited Top-Line FiguresJune 9, 2023 | finance.yahoo.comMedacta Group's (VTX:MOVE) Returns On Capital Not Reflecting Well On The BusinessMay 26, 2023 | finance.yahoo.comInvestors three-year returns in Medacta Group (VTX:MOVE) have not grown faster than the company's underlying earnings growthMay 5, 2023 | markets.businessinsider.comMedacta showcases NextAR Spine MIS LT procedure at Spine Week, efficiently complementing operative workflow for spine surgeryApril 27, 2023 | markets.businessinsider.comMedacta Group SA: Medacta announces the results of today's Annual General MeetingApril 11, 2023 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Medacta Group SA (VTX:MOVE)?March 29, 2023 | markets.businessinsider.comMedacta publishes 2023 Annual General Meeting invitationSee More Headlines Receive MEDGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolOTCMKTS:MEDGF CUSIPN/A CIKN/A Webwww.medacta.com Phone41 91 696 60 60FaxN/AEmployees1,662Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Alberto Siccardi (Age 80)Founder & Non Executive Chairman Comp: $361.87kDr. Francesco Siccardi (Age 47)Chief Executive Officer Comp: $1.75MMr. Corrado Farsetta (Age 56)Chief Financial Officer Gianluca OlgiatiSenior Director of Global MarketingAsif HussainChief People OfficerMr. Alessandro Siccardi (Age 38)Chief Supply Chain Officer Filippo CappelliHead of ITGiovanni Niccolo GalliChief Commercial OfficerMassimiliano BernardoniChief Innovation OfficerDonato CortesiSecretary of the BoardMore ExecutivesKey CompetitorsAinosNASDAQ:AIMDWBICO Group AB (publ)OTCMKTS:CLLKFBone BiologicsNASDAQ:BBLGWCaliber Imaging & DiagnosticsOTCMKTS:LCDXCell MedXOTCMKTS:CMXCView All Competitors MEDGF Stock Analysis - Frequently Asked Questions Should I buy or sell Medacta Group stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medacta Group in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEDGF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDGF, but not buy additional shares or sell existing shares. View MEDGF analyst ratings or view top-rated stocks. How have MEDGF shares performed in 2024? Medacta Group's stock was trading at $83.91 at the start of the year. Since then, MEDGF shares have increased by 0.0% and is now trading at $83.91. View the best growth stocks for 2024 here. How do I buy shares of Medacta Group? Shares of MEDGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEDGF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medacta Group SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
